Danaher To Acquire CDMO Aldevron for $9.6 Bn

By Miranda Greenberg -

June 17, 2021

Danaher Corporation, an industrial and life-sciences company, has agreed to acquire Aldevron, a CDMO of DNA plasmid, mRNA, and proteins, for approximately $9.6 billion.

The acquisition will add to Danaher’s life-sciences business, which includes Cytiva (formerly GE Healthcare Life Sciences, which Danaher acquired in 2020 for $21.4 billion), Pall, and Beckman Coulter Life Sciences. Following the close of the transaction, Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.

EQT Private Equity, which acquired Aldevron in 2019, agreed to sell Aldevron to Danaher.

Founded in 1998, Aldevron is headquartered in Fargo, North Dakota and employs approximately 600 people and has facilities in Fargo and Madison, Wisconsin. Aldevron is supplying plasmid DNA to Moderna for Moderna’s COVID-19 vaccine. Aldevron’s production of plasmid DNA takes place in its 70,000-square-foot GMP facility in Fargo. Buildout and validation of an additional 189,000-square-foot expansion has been completed for additional manufacturing capacity.

The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

Source: Danaher Corporation and EQT